27 completed. 27 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 27 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Infectious Encephalitis: new trials by email Literature Review of Infectious Encephalitis trials Research Report on Infectious Encephalitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age JEVAX, JECEVAX - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 220 | 2017-06-02 | 2018-09-17 |
| Safety and Immunogenicity of JECEVAX in Young Children JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 200 | 2015-04-01 | 2016-06-28 |
| New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 250 | 2015-01-01 | 2021-02-10 |
| Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients TBE virus vaccine - Tick Borne Encephalitis | Phase 2 | Completed | Medical University of Vienna | 34 | 2014-07-01 | 2022-02-03 |
| The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Japanese Encephalitis vaccine, Yellow Fever vaccine - Yellow Fever, Encephalitis, Japanese | Phase 2 | Completed | Singapore General Hospital | 84 | 2013-10-01 | 2016-04-20 |
| Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 200 | 2011-09-01 | 2015-11-18 |
| Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)] - Japanese Encephalitis | Phase 2 | Completed | University of Liverpool | 22 | 2009-05-01 | 2013-05-21 |
| Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults ChimeriVax-WN02 vaccine, Placebo - West Nile Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 479 | 2008-10-01 | 2015-04-03 |
| Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine Inactivated, Dried, TSI-GSD 104, EEE - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2019-09-24 |
| Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2020-03-17 |
| Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28) - Japanese Encephalitis, Hepatitis A | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2008-03-01 | 2014-10-02 |
| Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age ChimeriVax™-JE, Japanese Encephalitis Inactivated Mouse Brain Vaccine - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 96 | 2007-01-01 | 2012-08-27 |
| Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose - West Nile Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 208 | 2005-12-01 | 2016-04-14 |
| A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX ChimeriVax™-JE vaccine, JE-VAX® vaccine - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 60 | 2005-05-01 | 2012-08-20 |
| Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) Enfuvirtide, Tenofovir-Emtricitabine - Leukoencephalopathy, Progressive Multifocal, HIV Infections | Phase 2 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 30 | 2005-04-01 | 2026-04-02 |
| Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine Live attenuated Japanese encephalitis virus, ChimeriVax™ diluent (Placebo) - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 128 | 2004-11-01 | 2012-12-05 |
| Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Live attenuated Japanese encephalitis virus; Yellow fever virus, Yellow fever virus; Live attenuated Japanese encephalitis virus - Japanese Encephalitis, Yellow Fever | Phase 2 | Completed | Sanofi | 108 | 2004-07-01 | 2012-09-20 |
| A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus - Encephalitis, Japanese Encephalitis | Phase 2 | Completed | Sanofi | 202 | 2003-04-01 | 2012-07-16 |
| Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine - Rabies, Japanese Encephalitis | Phase 2 | Completed | Novartis | 200 | 2002-08-01 | 2008-06-10 |
Showing 20 of 27. Sign in to see all of them.
Encephalitis, Japanese (12) · Encephalitis, Tick-Borne (8) · HIV Infections (3) · Leukoencephalopathy, Progressive Multifocal (3) · Encephalomyelitis, Eastern Equine (2) · West Nile Fever (2) · Yellow Fever (2) · AIDS-Related Opportunistic Infections (1) · Acquired Immunodeficiency Syndrome (1) · Encephalitis (1) · Hepatitis A (1) · Rabies (1) · Viremia (1)
Brain Diseases (27) · Central Nervous System Diseases (27) · Central Nervous System Infections (27) · Central Nervous System Viral Diseases (27) · Encephalitis, Viral (27) · Infections (27) · Nervous System Diseases (27) · Neuroinflammatory Diseases (27) · RNA Virus Infections (27) · Virus Diseases (27) · Encephalitis (26) · Arbovirus Infections (24) · Encephalitis, Arbovirus (24) · Vector Borne Diseases (24)
Vaccines (3) · Desiccation (2) · Japanese Encephalitis Vaccines (2) · Saline Solution (2) · Cytarabine (1) · Didanosine (1) · Enfuvirtide (1) · FSME-IMMUN vaccine (1) · Filgrastim (1) · Hepatitis A Vaccines (1) · Immunoglobulins, Intravenous (1) · Topotecan (1) · Yellow Fever Vaccine (1) · Zalcitabine (1) · Zidovudine (1)
Pfizer (5) · Sanofi (5) · Sanofi Pasteur, a Sanofi Company (3) · National Institute of Hygiene and Epidemiology, Vietnam (2) · Sormland County Council, Sweden (2) · U.S. Army Medical Research and Development Command (2) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Medical University of Vienna (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis (1) · SK Bioscience Co., Ltd. (1) · Singapore General Hospital (1) · SmithKline Beecham (1) · University of Liverpool (1)
United States (7) · Australia (4) · Austria (4) · Germany (4) · Finland (2) · Sweden (2) · Thailand (2) · Vietnam (2) · France (1) · India (1) · Nepal (1) · New Zealand (1) · Singapore (1)
Robert Rivard, MD (2) · Thiem D Vu, MD., PhD. (2) · Ulrich Behre, MD (2) · Ajit Rayamajhi, MBBS, MD (1) · Anand Dubey, M.D (1) · Atul Shanker, Dr. (1) · Bakul B. Javadekar, M.D. (1) · Christina Forstner, MD (1) · Dominique Costagliola (1) · Hall C (1) · Jacques Gasnault, MD (1) · Jenny Low Guek Hong (1)
PMID 20856164, PMID 20864814, PMID 21148499, PMID 21150279, PMID 21738597, PMID 25872531, PMID 25886645, PMID 27686833, PMID 27815383, PMID 32728481, PMID 33899755, PMID 34452033, PMID 35101266
2005 (1)